EWTX
NASDAQ HealthcareEdgewise Therapeutics, Inc. - Common Stock
Biotechnology
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
๐ Market Data
| Price | $38.19 |
|---|---|
| Volume | 676,667 |
| Market Cap | 4.11B |
| Beta | 0.280 |
| RSI (14-Day) | 42.7 |
| 200-Day MA | $28.38 |
| 50-Day MA | $37.07 |
| 52-Week High | $48.40 |
| 52-Week Low | $12.30 |
| Forward P/E | -25.10 |
| Price / Book | 8.32 |
๐ฏ Investment Strategy Scores
EWTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (54/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ Over-Hyped (24/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find EWTX in your text
Paste any article, transcript, or post โ the tool will extract EWTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.